Spirax Group PLC
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
GBX 8,451.00 | Ywbf | Gwmzjwzm |
Spirax-Sarco’s First-Half Results Meet Our High Expectations; Shares Are Fairly Valued
Wide-moat Spirax-Sarco delivered an impressive first-half performance, delivering organic revenue growth of 15%, comfortably exceeding global industrial production growth of 2.9%. Growth was broad-based; however, Watson-Marlow continues to be the best performing segment, which grew 26%, driven by 30% sales growth to pharmaceutical customers, which account for 60% of the segment’s sales. The order book across all three businesses remains at all-time highs, which we anticipate will continue to support above-industry growth during the remainder of the year. We reiterate our GBX 11,800 fair value estimate and view shares as fairly valued.